Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.09
HOLX's Cash to Debt is ranked lower than
92% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. HOLX: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
HOLX' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.87 Max: No Debt
Current: 0.09
Equity to Asset 0.28
HOLX's Equity to Asset is ranked lower than
89% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. HOLX: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
HOLX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.67 Max: 0.88
Current: 0.28
0.22
0.88
Interest Coverage 2.77
HOLX's Interest Coverage is ranked lower than
85% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.00 vs. HOLX: 2.77 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 2.77
0.55
71.1
F-Score: 7
Z-Score: 1.07
M-Score: -2.75
WACC vs ROIC
6.42%
7.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.09
HOLX's Operating margin (%) is ranked higher than
83% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. HOLX: 18.09 )
Ranked among companies with meaningful Operating margin (%) only.
HOLX' s Operating margin (%) Range Over the Past 10 Years
Min: -123.18  Med: 8.28 Max: 20.93
Current: 18.09
-123.18
20.93
Net-margin (%) 7.48
HOLX's Net-margin (%) is ranked higher than
65% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. HOLX: 7.48 )
Ranked among companies with meaningful Net-margin (%) only.
HOLX' s Net-margin (%) Range Over the Past 10 Years
Min: -132.93  Med: -1.50 Max: 12.81
Current: 7.48
-132.93
12.81
ROE (%) 9.74
HOLX's ROE (%) is ranked higher than
64% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. HOLX: 9.74 )
Ranked among companies with meaningful ROE (%) only.
HOLX' s ROE (%) Range Over the Past 10 Years
Min: -59.07  Med: -0.73 Max: 13.4
Current: 9.74
-59.07
13.4
ROA (%) 2.68
HOLX's ROA (%) is ranked higher than
54% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. HOLX: 2.68 )
Ranked among companies with meaningful ROA (%) only.
HOLX' s ROA (%) Range Over the Past 10 Years
Min: -31.5  Med: -0.35 Max: 9.84
Current: 2.68
-31.5
9.84
ROC (Joel Greenblatt) (%) 66.61
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. HOLX: 66.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HOLX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 90.76
Current: 66.61
-369.68
90.76
Revenue Growth (3Y)(%) 7.20
HOLX's Revenue Growth (3Y)(%) is ranked higher than
61% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. HOLX: 7.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HOLX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.9  Med: 10.30 Max: 35.9
Current: 7.2
-7.9
35.9
EBITDA Growth (3Y)(%) 23.40
HOLX's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. HOLX: 23.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HOLX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.1  Med: 37.85 Max: 89.6
Current: 23.4
-5.1
89.6
» HOLX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

HOLX Guru Trades in Q2 2015

RS Investment Management 549,790 sh (New)
Carl Icahn 34,154,879 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Ken Fisher 128,300 sh (unchged)
Paul Tudor Jones Sold Out
Kahn Brothers 1,359,812 sh (-1.31%)
Murray Stahl 24,370 sh (-6.80%)
Jim Simons 174,400 sh (-88.38%)
» More
Q3 2015

HOLX Guru Trades in Q3 2015

Pioneer Investments 21,974 sh (New)
Joel Greenblatt 561,229 sh (New)
Steven Cohen 237,500 sh (New)
Paul Tudor Jones 20,500 sh (New)
RS Investment Management 921,560 sh (+67.62%)
Prem Watsa 20,000 sh (unchged)
Jim Simons Sold Out
Kahn Brothers 1,342,012 sh (-1.31%)
Vanguard Health Care Fund 6,159,700 sh (-16.53%)
Carl Icahn 28,154,879 sh (-17.57%)
Murray Stahl 17,042 sh (-30.07%)
Ken Fisher 47,632 sh (-62.87%)
» More
Q4 2015

HOLX Guru Trades in Q4 2015

Jim Simons 1,667,118 sh (New)
Pioneer Investments 147,180 sh (+569.79%)
Steven Cohen 998,300 sh (+320.34%)
RS Investment Management 1,142,810 sh (+24.01%)
Kahn Brothers 1,350,251 sh (+0.61%)
Carl Icahn 28,154,879 sh (unchged)
Prem Watsa Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 47,600 sh (-0.07%)
Vanguard Health Care Fund 5,802,700 sh (-5.80%)
Murray Stahl 15,126 sh (-11.24%)
Joel Greenblatt 384,989 sh (-31.40%)
» More
Q1 2016

HOLX Guru Trades in Q1 2016

Ken Fisher 47,620 sh (+0.04%)
Vanguard Health Care Fund 5,802,700 sh (unchged)
Murray Stahl Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Hologic Inc

Carl Icahn Continues to Reduce Position in Hologic Guru slashes more than 3 million shares from his portfolio
Guru Carl Icahn (Trades, Portfolio) reduced his position in Hologic Inc. (NASDAQ:HOLX), slashing 3,346,767 shares from his portfolio Monday. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 47.00
HOLX's P/E(ttm) is ranked lower than
73% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.55 vs. HOLX: 47.00 )
Ranked among companies with meaningful P/E(ttm) only.
HOLX' s P/E(ttm) Range Over the Past 10 Years
Min: 25.24  Med: 62.27 Max: 470.18
Current: 47
25.24
470.18
Forward P/E 15.87
HOLX's Forward P/E is ranked higher than
79% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.16 vs. HOLX: 15.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 47.00
HOLX's PE(NRI) is ranked lower than
73% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.55 vs. HOLX: 47.00 )
Ranked among companies with meaningful PE(NRI) only.
HOLX' s PE(NRI) Range Over the Past 10 Years
Min: 25.41  Med: 61.31 Max: 446.67
Current: 47
25.41
446.67
Price/Owner Earnings (ttm) 16.22
HOLX's Price/Owner Earnings (ttm) is ranked higher than
86% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.94 vs. HOLX: 16.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HOLX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.78  Med: 24.69 Max: 311.63
Current: 16.22
9.78
311.63
P/B 4.57
HOLX's P/B is ranked lower than
70% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. HOLX: 4.57 )
Ranked among companies with meaningful P/B only.
HOLX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 2.01 Max: 9.82
Current: 4.57
0.59
9.82
P/S 3.51
HOLX's P/S is ranked lower than
60% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. HOLX: 3.51 )
Ranked among companies with meaningful P/S only.
HOLX' s P/S Range Over the Past 10 Years
Min: 1.45  Med: 2.92 Max: 7.67
Current: 3.51
1.45
7.67
PFCF 14.19
HOLX's PFCF is ranked higher than
83% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.31 vs. HOLX: 14.19 )
Ranked among companies with meaningful PFCF only.
HOLX' s PFCF Range Over the Past 10 Years
Min: 6.45  Med: 15.23 Max: 528.13
Current: 14.19
6.45
528.13
POCF 12.51
HOLX's POCF is ranked higher than
67% of the 100 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.04 vs. HOLX: 12.51 )
Ranked among companies with meaningful POCF only.
HOLX' s POCF Range Over the Past 10 Years
Min: 5.45  Med: 13.48 Max: 140.85
Current: 12.51
5.45
140.85
EV-to-EBIT 27.25
HOLX's EV-to-EBIT is ranked lower than
65% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.75 vs. HOLX: 27.25 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 30.25 Max: 153.7
Current: 27.25
-137.4
153.7
EV-to-EBITDA 13.43
HOLX's EV-to-EBITDA is ranked higher than
61% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.31 vs. HOLX: 13.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 13.70 Max: 100.6
Current: 13.43
-344.2
100.6
Current Ratio 1.30
HOLX's Current Ratio is ranked lower than
83% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.64 vs. HOLX: 1.30 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.70 Max: 7.31
Current: 1.3
1.07
7.31
Quick Ratio 0.96
HOLX's Quick Ratio is ranked lower than
76% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. HOLX: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.11 Max: 6.57
Current: 0.96
0.85
6.57
Days Inventory 83.68
HOLX's Days Inventory is ranked higher than
76% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.92 vs. HOLX: 83.68 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.59 Max: 108.2
Current: 83.68
65.34
108.2
Days Sales Outstanding 55.38
HOLX's Days Sales Outstanding is ranked higher than
65% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.57 vs. HOLX: 55.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.15  Med: 63.27 Max: 85.65
Current: 55.38
56.15
85.65
Days Payable 34.25
HOLX's Days Payable is ranked lower than
76% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. HOLX: 34.25 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 39.3
Current: 34.25
21.81
39.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.53
HOLX's Price/Projected FCF is ranked higher than
65% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. HOLX: 1.53 )
Ranked among companies with meaningful Price/Projected FCF only.
HOLX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.41  Med: 1.27 Max: 12.14
Current: 1.53
0.41
12.14
Price/Median PS Value 1.21
HOLX's Price/Median PS Value is ranked lower than
60% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. HOLX: 1.21 )
Ranked among companies with meaningful Price/Median PS Value only.
HOLX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 0.87 Max: 2.57
Current: 1.21
0.15
2.57
Earnings Yield (Greenblatt) (%) 3.66
HOLX's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. HOLX: 3.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HOLX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 2.80 Max: 7.2
Current: 3.66
0.7
7.2
Forward Rate of Return (Yacktman) (%) 26.78
HOLX's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.62 vs. HOLX: 26.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HOLX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 0.1  Med: 6.70 Max: 72.6
Current: 26.78
0.1
72.6

More Statistics

Revenue(Mil) $2785
EPS $ 0.72
Beta0.81
Short Percentage of Float4.61%
52-Week Range $31.84 - 43.00
Shares Outstanding(Mil)278.83

Analyst Estimate

Sep16 Sep17 Sep18
Revenue(Mil) 2,820 2,929 3,069
EPS($) 1.88 2.16 2.38
EPS without NRI($) 1.88 2.16 2.38

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:MTD, NAS:XRAY, NYSE:RMD, NYSE:COO, NAS:SIRO » details
Traded in other countries:HO1.Germany,
Hologic Inc was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on Breast Health, GYN surgical and Skeletal Health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Carl Icahn Continues to Reduce Position in Hologic Apr 07 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
Carl Icahn Makes Big Transactions in 3rd Quarter Jan 03 2016 
Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Prem Watsa's Best Performing Holdings Oct 11 2015 
Carl Icahn Provides Update on Freeport-McMoRan Oct 07 2015 
Weekly 52-Week Highs Highlight: STI, GS, HOLX, MHK Jun 09 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 

More From Other Websites
Hologic, Inc. -- Moody's upgrades ratings on Hologic; CFR to Ba2 May 04 2016
Hologic to Webcast Presentations at Upcoming Investor Conferences May 03 2016
Hologic to Webcast Presentations at Upcoming Investor Conferences May 03 2016
HOLOGIC INC Financials May 03 2016
Hologic Marks National Osteoporosis Month by Releasing New Consumer Survey May 03 2016
New Study Further Supports Screening with Pap+HPV Together™ as Best Way to Detect Cervical Cancer... May 03 2016
Hologic Announces Financial Results for Second Quarter of Fiscal 2016 May 02 2016
Hologic Marks National Osteoporosis Month by Releasing New Consumer Survey May 02 2016
Hologic, Inc. breached its 50 day moving average in a Bearish Manner : HOLX-US : April 29, 2016 Apr 29 2016
Hologic (HOLX) Stock Tumbles Despite Q2 Earnings, Revenue Beat Apr 28 2016
Icahn on Hologic Apr 28 2016
Hologic (HOLX) Q2 Earnings, Revenues Top; FY16 View Up Apr 28 2016
Hologic downgraded by Needham Apr 28 2016
Edited Transcript of HOLX earnings conference call or presentation 27-Apr-16 8:30pm GMT Apr 28 2016
Hologic tops Street 2Q forecasts Apr 27 2016
Hologic tops Street 2Q forecasts Apr 27 2016
Study Results Published in JAMA Conclude that 3D MAMMOGRAPHY™ Exams Outperform Conventional... Apr 27 2016
HOLOGIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 27 2016
Hologic Announces Financial Results for Second Quarter of Fiscal 2016 Apr 27 2016
Koninklijke Philips Reported Mixed Quarterly Results for 1Q16 Apr 27 2016
Q2 2016 Hologic Inc Earnings Release - After Market Close Apr 27 2016
Study Results Published in JAMA Conclude that 3D MAMMOGRAPHY™ Exams Outperform Conventional... Apr 26 2016
Med-Instrument Stocks to Post Earnings: EW, HOLX, TMO, VAR Apr 25 2016
Can Hologic (HOLX) Pull a Surprise in Q2 Earnings? Apr 22 2016
Hologic Announces FDA Clearance and Commercial Availability of the Affirm™ Prone Biopsy System,... Apr 21 2016
Hologic Announces FDA Clearance and Commercial Availability of the Affirm™ Prone Biopsy System,... Apr 21 2016
Billionaires Paulson and Icahn Trim Stakes In 2 Companies; Plus Latest News on 2 Proxy Fights Apr 15 2016
Hologic Set to Join the S&P 500 Apr 12 2016
Systematic Review of Literature Further Validates that Breast Tomosynthesis Apr 05 2016
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are... Apr 01 2016
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2016 on Wednesday, April 27,... Apr 01 2016
Hologic Announces Financial Results for First Quarter of Fiscal 2016 Jan 27 2016
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are... Jan 04 2016
Hologic to Announce Financial Results for the First Quarter of Fiscal 2016 on Wednesday, January 27,... Jan 04 2016
Hologic Applauds Passage of Federal Measures that Preserve Access to Mammography for Breast Cancer... Dec 21 2015
Hologic to Present at the 34th Annual J.P. Morgan Healthcare Conference Dec 21 2015
Hologic Launches First Fully Automated, Sample-to-Result Molecular Assay for Mycoplasma genitalium... Dec 16 2015
Hologic Expands its European Virology Portfolio with CE-IVD Certified Assay for Hepatitis B Virus... Dec 10 2015
Hologic’s 3D MAMMOGRAPHY™ Bus Takes Center Stage as Company Sponsors 11th Annual Massachusetts... Dec 10 2015
Hologic to Present at the 27th Annual Piper Jaffray Healthcare Conference Nov 23 2015
Hologic Ranks First in Mammography Category Six Years Running, Says Annual "Best in KLAS" Survey of... Nov 16 2015
New Modeling Analysis Shows Screening for Cervical Cancer with Pap+HPV Together™ Could Provide... Nov 12 2015
Hologic beats Street 4Q forecasts Nov 04 2015
Hologic shares climb on 3Q results and boost to outlook Jul 29 2015
Hologic beats Street 3Q forecasts Jul 29 2015
Hologic tops Street 2Q forecasts Apr 29 2015
Hologic beats Street 1Q forecasts Jan 28 2015
Hologic tops Street 4Q forecasts Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK